Presented By: U-M College of Pharmacy
Self-Assembled Supramolecular Nanosystems for Smart Diagnosis and Targeted Therapy of Intractable Diseases
The College of Pharmacy invites you to the 22nd Annual John G. Wagner Memorial Lecture, presented by Dr. Kazunori Kataoka, Innovation Center of NanoMedicine, Kawasaki Institute of Industrial Promotion, and Policy Alternatives Research Institute, The University of Tokyo.
Nanotechnology-based medicine (Nanomedicine) has received progressive interest for the treatment of intractable diseases, such as cancer, as well as for the non-invasive diagnosis through various imaging modalities. Engineered polymeric nanosystems with smart functions play a key role in nanomedicine as drug carriers, gene vectors, and imaging probes. This presentation focuses present status and future trends of self-assembled nanosystems from block copolymers for the therapy and the non-invasive diagnosis of intractable diseases. Nanosystems with 10 to 100 nm in size can be prepared by programmed self-assembly of block copolymers in aqueous entity. Most typical example is polymeric micelles (PMs) with distinctive core-shell architecture. Compared with conventional formulations, such as liposomes, PMs have several advantages, including controlled drug release, tissue penetrating ability and reduced toxicity [1,2]. Notable anti-tumor efficacy against intractable and metastatic cancer, including pancreatic cancer [3], glioblastoma [4,5], and cancer stem cells [6], of antitumor drug incorporated PMs with pH- and/or redox potential responding properties was demonstrated, emphasizing their promising utility in cancer treatment. Versatility in drug incorporation is another feasibility of PMs. Loading of imaging reagents makes PMs with theranostic functions [7].
These results demonstrate the promising features of PMs as platform nanosystems for molecular therapy of various intractable diseases. Very recently, we developed PMs decorated with glucose to crossing blood-brain barrier by recognizing glucose-transporter overexpressing on brain endothelial cells, opening new avenue to deliver versatile drugs for the treatment of neurodegenerative diseases, including Alzheimer’s disease [8].
References
[1] H. Cabral, K. Kataoka, J. Contrl. Rel. 190, 70 (2014).
[2] Y. Matsumoto, et al, Nature Nanotech. 11, 533 (2016).
[3] H. Cabral, et al, ACS Nano 9, 4957 (2015).
[4] K. Katsushima, et al, Nature Commun. 7, 13616 (2016).
[5] S. Quader, et al, J. Contrl. Rel. 258, 56 (2017).
[6] H. Kinoh, et al, ACS Nano 10, 5643 (2016).
[7] P. Mi, et al, Nature Nanotech. 11, 724 (2016).
[8] Y. Anraku, et al, Nature Commun. 8, 1001 (2017).
Nanotechnology-based medicine (Nanomedicine) has received progressive interest for the treatment of intractable diseases, such as cancer, as well as for the non-invasive diagnosis through various imaging modalities. Engineered polymeric nanosystems with smart functions play a key role in nanomedicine as drug carriers, gene vectors, and imaging probes. This presentation focuses present status and future trends of self-assembled nanosystems from block copolymers for the therapy and the non-invasive diagnosis of intractable diseases. Nanosystems with 10 to 100 nm in size can be prepared by programmed self-assembly of block copolymers in aqueous entity. Most typical example is polymeric micelles (PMs) with distinctive core-shell architecture. Compared with conventional formulations, such as liposomes, PMs have several advantages, including controlled drug release, tissue penetrating ability and reduced toxicity [1,2]. Notable anti-tumor efficacy against intractable and metastatic cancer, including pancreatic cancer [3], glioblastoma [4,5], and cancer stem cells [6], of antitumor drug incorporated PMs with pH- and/or redox potential responding properties was demonstrated, emphasizing their promising utility in cancer treatment. Versatility in drug incorporation is another feasibility of PMs. Loading of imaging reagents makes PMs with theranostic functions [7].
These results demonstrate the promising features of PMs as platform nanosystems for molecular therapy of various intractable diseases. Very recently, we developed PMs decorated with glucose to crossing blood-brain barrier by recognizing glucose-transporter overexpressing on brain endothelial cells, opening new avenue to deliver versatile drugs for the treatment of neurodegenerative diseases, including Alzheimer’s disease [8].
References
[1] H. Cabral, K. Kataoka, J. Contrl. Rel. 190, 70 (2014).
[2] Y. Matsumoto, et al, Nature Nanotech. 11, 533 (2016).
[3] H. Cabral, et al, ACS Nano 9, 4957 (2015).
[4] K. Katsushima, et al, Nature Commun. 7, 13616 (2016).
[5] S. Quader, et al, J. Contrl. Rel. 258, 56 (2017).
[6] H. Kinoh, et al, ACS Nano 10, 5643 (2016).
[7] P. Mi, et al, Nature Nanotech. 11, 724 (2016).
[8] Y. Anraku, et al, Nature Commun. 8, 1001 (2017).
Related Links
Explore Similar Events
-
Loading Similar Events...
